Direct accesses
Go to main menu
Go to main content
Menu
Search the site
Contact
Careers
You are viewing the website in English
en
fr
Search the site
Who
we are
Company
Leadership
Collaborations
Diseases
we target
Diseases we target
Leber Hereditary Optic Neuropathy (LHON)
Retinitis Pigmentosa (RP)
Geographic Atrophy in Dry-AMD
Our
technologies
Technologies we are applying
Gene Therapy
Mitochondrial Targeting Sequence (MTS)
Optogenetics
Clinical development Summary
Investors
Company Overview
Financial press releases
Investor Newsletters
Events & presentations
Stock information & Financial agenda
Governance
Documentation
Media
Press Releases
Year
All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
News type
All
Regulatory
Clinical
Conferences
Corporate
Finance
General Meeting
Product candidates
Science & Technology
Other
Subject
All
General Assembly
Company and personnel
GS010 - LUMEVOQ
GS030
Technologies
Other
07 May 2019
GenSight Biologics announces positive Data Safety Monitoring Board review and continuation of PIONEER Phase I/II clinical trial of GS030 combining gene therapy and Optogenetics for the treatment of Retinitis Pigmentosa
06 May 2019
GenSight Biologics announces presentation of 72-week data from the REVERSE Phase III trial of GS010 at the Annual Meeting of the American Academy of Neurology (AAN)
29 April 2019
GenSight Biologics Announces the Filing of its 2018 Annual Financial Report
25 April 2019
GenSight Biologics announces presentation of 72-week data from the REVERSE & RESCUE Phase III trials of GS010 at the Annual Meeting of ARVO
24 April 2019
GenSight Biologics Reports Full Year 2018 Financial Results
23 April 2019
GenSight Biologics Reports its Cash Position as of March 31, 2019
17 April 2019
GenSight Biologics reports positive follow-up results at Week 72 of the RESCUE Phase III clinical trial of GS010 in Leber Hereditary Optic Neuropathy (LHON)
15 March 2019
GenSight Biologics announces presentation of 72-week data from the REVERSE Phase III trial of GS010 at the 45th annual meeting of NANOS
25 February 2019
GenSight Biologics completes a capital increase of €8 million without discount subscribed entirely by Sofinnova
12 February 2019
GenSight Biologics announces publication of positive safety data from Phase I/II trial of GS010 in the JAMA Ophthalmology
View previous 9 articles
1
…
12
13
14
15
16
17
18
19
20
21
22
…
24
View next 9 articles
Go back to the page of the page